SG11202105302PA - Dll3-targeting multispecific antigen-binding molecules and uses thereof - Google Patents

Dll3-targeting multispecific antigen-binding molecules and uses thereof

Info

Publication number
SG11202105302PA
SG11202105302PA SG11202105302PA SG11202105302PA SG11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA
Authority
SG
Singapore
Prior art keywords
dll3
binding molecules
multispecific antigen
targeting
targeting multispecific
Prior art date
Application number
SG11202105302PA
Other languages
English (en)
Inventor
Sotaro Naoi
Shu Feng
Tomoyuki Igawa
Shu Wen Samantha Ho
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202105302PA publication Critical patent/SG11202105302PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202105302PA 2020-03-31 2021-03-30 Dll3-targeting multispecific antigen-binding molecules and uses thereof SG11202105302PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062326 2020-03-31
PCT/JP2021/013460 WO2021200898A1 (en) 2020-03-31 2021-03-30 Dll3-targeting multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11202105302PA true SG11202105302PA (en) 2021-11-29

Family

ID=77855554

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105302PA SG11202105302PA (en) 2020-03-31 2021-03-30 Dll3-targeting multispecific antigen-binding molecules and uses thereof

Country Status (18)

Country Link
US (3) US11274151B2 (de)
EP (1) EP4126969A4 (de)
JP (2) JP7085666B2 (de)
KR (2) KR102505383B1 (de)
CN (1) CN115397866A (de)
AR (1) AR121695A1 (de)
AU (1) AU2021250186A1 (de)
BR (1) BR112022019498A2 (de)
CA (1) CA3173587A1 (de)
CL (1) CL2022002624A1 (de)
CO (1) CO2022015305A2 (de)
CR (1) CR20220541A (de)
IL (1) IL296803A (de)
MX (1) MX2022012091A (de)
PE (1) PE20230077A1 (de)
SG (1) SG11202105302PA (de)
TW (2) TWI799824B (de)
WO (1) WO2021200898A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015068847A1 (ja) 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
WO2019131988A1 (en) * 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
KR102505383B1 (ko) 2020-03-31 2023-03-02 추가이 세이야쿠 가부시키가이샤 Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
JP2023519776A (ja) * 2020-03-31 2023-05-15 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0328966Y2 (de) 1987-10-16 1991-06-20
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
US6955900B1 (en) 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
CN1237076C (zh) 1999-01-15 2006-01-18 杰南技术公司 具有改变的效应功能的多肽变体
AU2757500A (en) 1999-02-10 2000-08-29 Human Genome Sciences, Inc. 33 human secreted proteins
EP1206487A2 (de) 1999-08-19 2002-05-22 Chiron Corporation Notch rezeptor ligande und deren verwendung
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7534604B2 (en) 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
CN101014619B (zh) 2004-07-15 2010-11-03 赞科股份有限公司 优化的Fc变体
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
RU2007118954A (ru) 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
CN101123983A (zh) 2004-10-27 2008-02-13 米迪缪尼股份有限公司 特定修饰对相关抗原的亲和力来调节抗体的特异性
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ATE548386T1 (de) 2005-01-05 2012-03-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
CA2596248A1 (en) 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
EP1870459B1 (de) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur polypeptidherstellung mit regulation des zusammenbaus
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
CA2637267A1 (en) 2006-01-16 2007-07-19 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
US20080227958A1 (en) 2006-04-14 2008-09-18 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2007311957A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP2010524851A (ja) 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2009025846A2 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
CA2713281C (en) 2008-01-31 2019-10-15 Dimiter S. Dimitrov Engineered antibody constant domain molecules
EP2260058A2 (de) 2008-04-07 2010-12-15 Ablynx N.V. Variable einzeldomänen gegen notch-signalwege
CN102143977B (zh) 2008-09-03 2014-08-06 霍夫曼-拉罗奇有限公司 多特异性抗体
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
PT2530091T (pt) 2010-01-29 2018-05-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-dll3
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
CN108341868B (zh) 2010-11-05 2022-06-07 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
EP4279511A3 (de) 2010-11-30 2024-01-24 Chugai Seiyaku Kabushiki Kaisha Zytotoxizität induzierendes therapeutikum
US9469685B2 (en) 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
SI2714733T1 (sl) 2011-05-21 2019-06-28 Macrogenics, Inc. CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
HUE038225T2 (hu) 2011-08-23 2018-10-29 Roche Glycart Ag Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
PL3418306T3 (pl) 2011-10-11 2024-04-15 F. Hoffmann-La Roche Ag Ulepszone składanie przeciwciał dwuswoistych
AU2012325915A1 (en) 2011-10-20 2014-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
RS56443B1 (sr) 2012-02-24 2018-01-31 Abbvie Stemcentrx Llc Ddl3 modulatori i postupci primene
EP2857420B1 (de) 2012-05-30 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Zielgewebespezifisches antigenbindendes molekül
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JPWO2015068847A1 (ja) 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
SG11201606898TA (en) 2014-02-21 2016-09-29 Stemcentrx Inc Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2940451A1 (en) 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2015146438A1 (ja) 2014-03-26 2015-10-01 国立大学法人東北大学 ヒト上皮増殖因子受容体を標的とした二重特異性抗体
BR112016022912A2 (pt) 2014-04-07 2017-10-17 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno de imunoativação
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
AR101936A1 (es) 2014-07-31 2017-01-25 Amgen Res (Munich) Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
EP2982692A1 (de) * 2014-08-04 2016-02-10 EngMab AG Bispezifische Antikörper gegen CD3-Epsilon und BCMA
EP3388449A3 (de) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cystein-manipulierte antikörper und konjugate
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
EP3305322A4 (de) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Kombinierte verwendung von immunaktivatoren
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EP3452502B1 (de) 2016-05-02 2021-03-03 H. Hoffnabb-La Roche Ag Contorsbody - ein kreisförmiger einkettiger targetbinder
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN117752798A (zh) 2016-12-19 2024-03-26 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
BR112019022751A2 (pt) 2017-05-05 2020-05-19 Amgen Inc composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
WO2019111871A1 (en) * 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
WO2019131988A1 (en) * 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
TW202016151A (zh) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3831854A4 (de) 2018-08-03 2022-05-04 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül mit zwei miteinander verbundenen antigenbindenden domänen
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
WO2020067399A1 (en) 2018-09-28 2020-04-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
WO2020076977A2 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
JP2023512390A (ja) 2020-02-05 2023-03-27 中外製薬株式会社 組換え抗原結合分子を製造するおよび／または濃縮するための方法
JP2023519776A (ja) 2020-03-31 2023-05-15 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
KR102505383B1 (ko) 2020-03-31 2023-03-02 추가이 세이야쿠 가부시키가이샤 Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용

Also Published As

Publication number Publication date
US20210301016A1 (en) 2021-09-30
CA3173587A1 (en) 2021-10-07
EP4126969A4 (de) 2024-05-29
CN115397866A (zh) 2022-11-25
CL2022002624A1 (es) 2023-06-02
CO2022015305A2 (es) 2022-11-08
KR20220100520A (ko) 2022-07-15
JP7085666B2 (ja) 2022-06-16
US20240010725A1 (en) 2024-01-11
BR112022019498A2 (pt) 2022-11-16
AU2021250186A1 (en) 2022-12-01
JP2021159081A (ja) 2021-10-11
AR121695A1 (es) 2022-06-29
US11718672B2 (en) 2023-08-08
WO2021200898A1 (en) 2021-10-07
EP4126969A1 (de) 2023-02-08
US20220251201A1 (en) 2022-08-11
US11274151B2 (en) 2022-03-15
PE20230077A1 (es) 2023-01-11
TWI799824B (zh) 2023-04-21
IL296803A (en) 2022-11-01
JP2022122972A (ja) 2022-08-23
KR20230035138A (ko) 2023-03-10
KR102505383B1 (ko) 2023-03-02
TW202204409A (zh) 2022-02-01
CR20220541A (es) 2022-11-28
MX2022012091A (es) 2022-10-13
TW202325741A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
SG11202105302PA (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
IL287848A (en) Multispecific antigen binding molecules and their uses
SG11202104264TA (en) Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
PL3818086T3 (pl) Leczenie i zapobieganie nowotworom złośliwym z zastosowaniem cząsteczek wiążących antygen HER3
EP3265575A4 (de) Cd20-bindende moleküle und verwendungen davon
IL290299A (en) Cell-targeting multispecific antigen-binding compounds and their uses
IL287765A (en) TIGIT and FDI-1/TIGIT binding molecules
SG11202105566TA (en) Immune activating multispecific antigen-binding molecules and uses thereof
KR101882072B1 (ko) 전이 금속 칼코겐화합물 채널을 갖는 전계 효과 트랜지스터 및 제조 방법
GB201709970D0 (en) Bispecific antigen-binding molecules
GB2587720B (en) Structural analysis of ionised molecules
EP3586872A4 (de) Pharmazeutische zusammensetzung, antigenbindende moleküle, behandlungsverfahren und screening-verfahren
EP3397262A4 (de) Kombination aus einem hdac-hemmer und einem anti-pd-l1-antikörper zur behandlung von eierstockkrebs
IL278832A (en) Improved molecules that bind 41GP
IL283087A (en) Multispecific binding structures against checkpoint compounds and their uses
IL273761A (en) Antigen-binding engineered cysteine molecules
IL276253A (en) Bispecific antigen binding molecules and methods of use
HK1245778A1 (zh) 用於治療原發性癌症和癌症擴散的小分子
GB201720426D0 (en) CD47 and BCMA antigen-binding molecules
EP3753956A4 (de) Antigenbindendes molekül und kombination
EP4114856A4 (de) Antigenbindende moleküle und verwendungen davon
IL284781A (en) LILRB3 binding molecules and uses thereof
GB202017717D0 (en) Improved small molecules
IL311096A (en) Antigen binding molecules and their uses
IL311696A (en) Uses of multispecific molecules bind antigens to DLL3